Minimizing Oncology Drug Failure Rates Using Organoid Modeling and Multi-Omic Data
Discover how organoids transform immuno-oncology drug development allowing the accurate prediction of patient response to treatment and the assessment of safety through multi-omic data analysis. Learn how the use of organoids that mimic the functional, structural, and molecular complexity of tumors improves the translatability of preclinical research and increases clinical trial success rates.
Sylvia F. Boj, Ph.D., Chief Scientific Officer at HUB Organoids and Daniella Patton, Ph.D., Principal Scientific Consultant at Genedata, demonstrate the innovative applications of organoid technology for drug development and how Genedata Profiler, the data integration and analytics solution, facilitates the extraction of actionable scientific insights to accelerate the delivery of the right treatment to the right patients.
Get Insights On:
- Establishing organoid co-cultures to model tumor and immune cell interaction in a dish
- Using organoids optimally to develop various immunotherapy modalities including engineered T cells, CAR-T therapies, or therapeutics targeting the myeloid compartment
- Streamlining the integration of multimodal data derived from these experiments on a single digital platform
- Leveraging highly performant, self-service analysis and visualization tools to efficiently extract insights to advance precision medicine development
Who Should Watch?
- Scientists conducting discovery, preclinical or clinical research seeking innovative disease models for exploration to develop precision medicine solutions
- Leaders in biopharma, biotech, or life sciences looking to accelerate clinical development
- Digitalization experts in pursuit of solutions to empower effective translational research and increase the value of R&D data
